Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Crucell Advances Hepatitis B Vaccine in China

publication date: Dec 10, 2008

The Dutch biopharma Crucell said the SFDA released its hepatitis B vaccine Hepavax-Gene® for registration and quality control in China. Crucell pointed out that Hepavax-Gene offers two advantages over competing products: its production is based on Crucell's hansenula polymorpha patented technology, a protein expression platform, and the vaccine is completely free of the mercury-based compound thiomersal. In many countries, thiomersal is being phased out from vaccines given to children because of potentially adverse effects. More details...
Stock Symbol: (NSDQ: CRXL)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital